Ying Du Sells 5,576 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 5,576 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $113,694.64. Following the completion of the sale, the chief executive officer owned 1,125,279 shares of the company’s stock, valued at approximately $22,944,438.81. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB opened at $20.41 on Friday. The business’s 50-day simple moving average is $18.67 and its 200 day simple moving average is $21.75. The company has a market cap of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%.The company had revenue of $127.60 million during the quarter. Analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada raised its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,771 shares of the company’s stock after buying an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ZLAB shares. UBS Group began coverage on shares of Zai Lab in a report on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. JPMorgan Chase & Co. lowered their target price on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Zacks Research lowered Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.